ZIOPHARM (ZIOP) Files Common Stock and Warrant Offering

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-lead managers for the offering.

The Company plans to use net proceeds from this offering for general corporate purposes, which may include ongoing clinical development of its three product candidates, palifosfamide (Zymafos or ZIO-201), darinaparsin (Zinapar or ZIO-101), and indibulin (Zybulin or ZIO-301).